Drug intelligence / Profile preview

PRT7732

Development stage: Unknown
Lead developer: Prelude Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

PRT7732 is a highly potent, selective, and orally bioavailable small molecule degrader of SMARCA2, developed by Prelude Therapeutics. It functions as a targeted protein degrader with near-absolute selectivity for SMARCA2 over SMARCA4 (>3000-fold in cellular assays). The drug is designed to treat advanced or metastatic solid tumors, particularly those harboring SMARCA4 mutations. Preclinical studies have demonstrated significant anti-tumor activity in SMARCA4-deficient cancer models. PRT7732 is currently being evaluated in Phase 1 clinical trials across multiple countries for patients with advanced malignant solid neoplasms and metastatic solid tumors.

Targets

SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily A member 2)

Beyond the preview

Go deeper on PRT7732.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT7732.

Explore the full profile